Exercise reduces immune suppression and breast cancer progression in a preclinical model
PDF | Full Text | How to cite
Metrics: PDF 2451 views | Full Text 4575 views | ?
Erik Wennerberg1,*, Claire Lhuillier1,*, Marissa D. Rybstein1, Kyle Dannenberg2, Nils-Petter Rudqvist1, Graeme J. Koelwyn2, Lee W. Jones2,5 and Sandra Demaria1,3,4
1 Department of Radiation Oncology, Weill Cornell Medical College, Stich Radiation Oncology, New York, NY, USA
2 Memorial Sloan Kettering Cancer Center, New York, NY, USA
3 Sandra and Edward Meyer Cancer Center, New York, NY, USA
4 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA
5 Department of Medicine, Weill Cornell Medical College, New York, NY, USA
* These authors contributed equally to this work
|Sandra Demaria,||email:||[email protected]|
Keywords: breast cancer; exercise training; immune cells; immunotherapy; myeloid-derived suppressor cells
Received: November 19, 2019 Accepted: January 13, 2020 Published: January 28, 2020
Exercise is associated with favorable changes in circulating immune cells and improved survival in early-stage breast cancer patients, but the mechansims remain to be fully elucidated. Preclinical studies indicate that physical activity started before tumor injection reduces tumor incidence and progression. Here we tested whether exercise has anti-tumor effects in mice with established 4T1 mammary carcinoma, a mouse model of triple negative breast cancer. Exercise slowed tumor progression and reduced the tumor-induced accumulation of myeloid-derived suppressor cells (MDSCs). The reduction in MDSCs was accompanied by a relative increase in natural killer and CD8 T cell activation, suggesting that exercise restores a favorable immune environment. Consistently, exercise improved responses to a combination of programmed cell death protein 1 (PD-1) blockade and focal radiotherapy. These data support further investigations of exercise in breast cancer patients treated with combinations of immunotherapy and cytotoxic agents to improve cancer outcomes.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.